| Literature DB >> 25392646 |
Shuodong Wu1, Xiao-Peng Yu1, Yu Tian1, Ernest Amos Siwo1, Yongnan Li1, Hong Yu1, Dianbo Yao1, Chao Lv1.
Abstract
BACKGROUND AND OBJECTIVES: Transumbilical single-incision laparoscopic surgery (SILS) is gaining in popularity as a minimally invasive technique. The reduced pain and superior cosmetic appearance it affords make it attractive to many patients. For this study, we focused on SILS, analyzing the outcomes of transumbilical single-incision laparoscopic liver resection (SILLR) achieved at our institution between January 2010 and February 2013. PATIENTS AND METHODS: Pre- and postoperative data from 17 patients subjected to transumbilical SILLR for various hepatic lesions (8 hemangiomas, 2 hepatocellular carcinomas, 2 metastases, 2 calculi of left intrahepatic duct, and 3 adenomas) were assessed. Altogether, eight wedge resections, seven left lateral lobectomies, a combination wedge resection/left lateral lobectomy, and a proximal left hemihepatectomy segmentectomy were performed, as well as four simultaneous laparoscopic cholecystectomies. In each instance, three ports were installed through an umbilical incision. Once vessels and bleeding were controlled, the lesion(s) were resected with 5-mm margins of normal liver. Resected tissues were then bagged and withdrawn through the umbilical incision. The follow-up period lasted for a minimum of 6 months.Entities:
Keywords: Hepatectomy; Laparoscopy; Single-incision surgery
Mesh:
Year: 2014 PMID: 25392646 PMCID: PMC4154436 DOI: 10.4293/JSLS.2014.00397
Source DB: PubMed Journal: JSLS ISSN: 1086-8089 Impact factor: 2.172
SILLR Cohort: Demographics and Interventions
| Patient No. | Age (y) | Gender | Lesion Type | Location | Size (cm) | Intervention |
|---|---|---|---|---|---|---|
| 40 | Male | Hepatic hemangioma and gallbladder polyp | S2, S3 | 5.4 × 4.1 | Single-incision LH left lateral lobectomy and cholecystectomy | |
| 2 | 56 | Male | Hepatic hemangioma | S5, S6 | 7.6 × 6.3 | Single-incision LH S5, S6 wedge resection and cholecystectomy |
| 3 | 61 | Male | Colon cancer and liver metastases | S2, S3 | 4.7 × 3.9 | Single-incision LH left lateral lobectomy and S8 wedge resection |
| 2.5 × 1.5 | ||||||
| 4 | 46 | Female | Left lateral lobe giant hemangioma | S2, S3 | 10.5 × 9.5 | Single-incision LH left lateral lobectomy |
| 5 | 50 | Female | Hepatic hemangioma | S2, S3 | 9.0 × 6.0 | Single-incision LH left lateral lobectomy |
| 6 | 60 | Male | Hepatic hemangioma | S2 | 4.5 × 4.0 | Single-incision LH S2 wedge resection |
| 7 | 50 | Female | Hepatocellular carcinoma (HCC) well-differentiated | S2, S3 | 3.3 × 2.6 | Single-incision LH S2 wedge resection |
| 8 | 35 | Female | Hepatic hemangioma | S2, S3 | 7.0 × 5.0 | Single-incision LH left lateral lobectomy |
| 9 | 34 | Female | Hepatic focal nodular hyperplasia (FNH) | S5, S6 | 6.2 × 4.0 | Single-incision LH S5 wedge resection |
| 10 | 56 | Female | Hepatic hemangioma | S2, S3 | 4.8 × 4.6 | Single-incision LH S2 wedge resection |
| 11 | 64 | Male | Hepatocellular carcinoma (HCC) well-differentiated | S8 | 3.0 × 2.5 | Single-incision LH S8 wedge resection |
| 12 | 48 | Male | Cholecystolithiasis and calculus of left intrahepatic duct | S2, S3 | — | Single-incision laparoscopic proximal left hemihepatectomy segmentectomy and cholecystectomy |
| 13 | 37 | Female | Liver adenoma | S4 | 4.0 × 3.0 | Single-incision LH S4 wedge resection |
| 14 | 32 | Female | Liver adenoma | S2, S3 | 10.0 × 8.0 | Single-incision LH left lateral lobectomy |
| 15 | 60 | Female | Hepatic hemangioma | S2, S3 | 5.0 × 3.0 | Single-incision LH left lateral lobectomy |
| 16 | 71 | Male | Cholecystolithiasis and calculus of intrahepatic duct | S2, S3 | — | Single-incision LH left lateral lobectomy |
| 17 | 58 | Male | Colon cancer and liver metastases | S5 | 2.0 × 2.0 | Single-incision LH S5 wedge resection and right colectomy |
LH, laparoscopic hepatectomy.
Patient Outcomes Post-SILLR
| Patient No. | Blood Loss (mL) | Operating Time (min) | Hospital Stay (d) | Days to Oral Intake (h) | Mortality[ | Postoperative Pain >5 d/Pain Score[ | |
|---|---|---|---|---|---|---|---|
| 1 | 120 | 155 | 7 | 40 | Alive | No/3 | |
| 2 | 830 | 175 | 8 | 44 | Alive | No/4 | |
| 3 | 800 | 185 | 10 | 48 | Expired 16 months postoperatively | Yes/6 | |
| 4 | 210 | 180 | 7 | 50 | Alive | No/4 | |
| 5 | 130 | 130 | 7 | 36 | Alive | No/2 | |
| 6 | 290 | 70 | 8 | 24 | Alive | No/3 | |
| 7 | 480 | 160 | 10 | 30 | Expired 18 months postoperatively | No/4 | |
| 8 | 220 | 115 | 8 | 48 | Alive | No/3 | |
| 9 | 200 | 115 | 6 | 45 | Alive | Yes/5 | |
| 10 | 310 | 85 | 7 | 51 | Alive | No/2 | |
| 11 | 180 | 55 | 8 | 55 | Alive with multiple metastases | No/3 | |
| 12 | 90 | 180 | 10 | 40 | Alive | No/5 | |
| 13 | 140 | 90 | 8 | 48 | Alive | No/4 | |
| 14 | 200 | 140 | 8 | 46 | Alive | No/3 | |
| 15 | 30 | 50 | 3 | 18 | Alive | No/2 | |
| 16 | 50 | 65 | 8 | 28 | Alive | No/2 | |
| 17 | 80 | 55 | 7 | 26 | Alive with no metastases | No/4 | |
| Total (N = 17) Percentage | Average | 256.47 ± 236.51 | 117.94 ± 49.21 | 7.65 ± 1.66 | 39.82 ± 10.93 | 11.76% | 11.76% |
VAS, visual analog scale.
Follow-up range was 6 to 42 months.
Highest recorded postoperative pain score.
Complications
| Patient No. | Pleural Effusion | Incisional Infection | Incisional Hernia | Hematoma Requiring Drainage, Abscess Requiring Drainage, Abdominal Infection | Upper GI Bleeding, Bile Duct Obstruction, Bile Leak | Overall Complication |
|---|---|---|---|---|---|---|
| 1 | No | No | No | No | No | 0 |
| 2 | No | No | No | No | No | 0 |
| 3 | No | No | No | No | No | 0 |
| 4 | No | Yes | No | No | No | 1 |
| 5 | No | No | No | No | No | 0 |
| 6 | No | No | No | No | No | 0 |
| 7 | No | No | No | No | No | 0 |
| 8 | No | No | No | No | No | 0 |
| 9 | No | No | Yes | No | No | 1 |
| 10 | No | No | No | No | No | 0 |
| 11 | No | No | No | No | No | 0 |
| 12 | No | Yes | No | No | No | 1 |
| 13 | No | No | No | No | No | 0 |
| 14 | No | No | No | No | No | 0 |
| 15 | Yes | No | No | No | No | 1 |
| 16 | No | No | No | No | No | 0 |
| 17 | No | No | No | No | No | 0 |
| Total (N = 17)/percentage | 1/5.88% | 2/11.76% | 1/5.88% | 0/0.00% | 0/0.00% | 4/23.53% |
GI, gastrointestinal.